blincyto - blinatumomab
(Blinatumomab)Amgen, Inc
Usage: BLINCYTO treats CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adults and pediatric patients (≥1 month) across three settings: MRD-positive disease (≥0.1%) in first or second remission, relapsed or refractory ALL, and Philadelphia chromosome-negative ALL during consolidation chemotherapy.